

CARACO PHARMACEUTICAL LABORATORIES LTD  
Form 8-K  
October 30, 2008  
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

October 30, 2008

(Date of report)

CARACO PHARMACEUTICAL LABORATORIES, LTD.

(Exact name of registrant as specified in its charter)

Michigan	0-24676	38-2505723
(State or other jurisdiction of incorporation)	(Commission file number)	(I.R.S. employer identification no.)

1150 Elijah McCoy Drive, Detroit, Michigan 48202

(Address of principal executive offices)

(313) 871-8400

(Registrant's telephone number, including area code)

Edgar Filing: CARACO PHARMACEUTICAL LABORATORIES LTD - Form 8-K

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 140.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01 Regulation FD Disclosure**

On October 30, 2008, Caraco Pharmaceutical Laboratories, Ltd. ("Caraco") is making a presentation to certain investors. The slides used in connection with such presentation are furnished in Exhibit 99.1 hereto. Caraco also intends to include such slide presentation on its website (<http://www.caraco.com>).

**Item 9.01. Financial Statements and Exhibits**

c) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
--------------------	--------------------

99.1	<u>Copy of the slides used in connection with Caraco's presentation to certain investors on October 30, 2008.</u>
------	---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CARACO PHARMACEUTICAL LABORATORIES, LTD.**

Date: October 30, 2008

By: /s/ Daniel H. Movens

\_\_\_\_\_

Daniel H. Movens

Chief Executive Officer

---

**Exhibit Index**

99.1 Copy of the slides used in connection with Caraco's presentation to certain investors on October 30, 2008.